title: A single dose of mirtazapine modulates neural responses to emotional faces in healthy people.
abstract: BACKGROUND
  Single-dose administration of selective serotonin and noradrenaline reuptake blockers has been shown to alter emotional processing in both behavioral and fMRI studies in healthy volunteers. Mirtazapine is a clinically established antidepressant with different pharmacological actions from monoamine reuptake inhibitors, involving blockade of noradrenaline α(2)-adrenoceptors and multiple 5-HT receptor subtypes. The aim of this study was to investigate the effect of a single dose of mirtazapine on the neural processing of emotional faces in healthy volunteers.
  
  
  METHODS
  Twenty-eight participants were randomized to receive either a single dose of mirtazapine (15 mg) or placebo. Two hours later, participants underwent an fMRI scan, in which they classified fearful and happy faces on the basis of gender. Mood and subjective experience were also measured.
  
  
  RESULTS
  Whole-brain analysis showed significant group × emotion interactions in a right amygdala-hippocampal region and left fronto-striatal cortex. Post hoc analyses revealed significantly reduced activation to fear and greater activation to happy faces in both regions under mirtazapine.
  
  
  CONCLUSIONS
  Our findings indicate that a single dose of mirtazapine modulates neural activity to affective stimuli. Mirtazapine was found to decrease neural responses to fear and increase responses to happy facial expressions in regions implicated in the processing of emotional faces. These effects may be important for our understanding of the neural mechanisms of antidepressant action in anxiety and depression.
authors.affiliation: Psychopharmacology and Emotion Research Laboratory, Department of Psychiatry, University of Oxford, Warneford Hospital, Neurosciences Building, Headington, Oxford, OX3 7JX, UK. nancy.rawlings@psych.ox.ac.uk
authors.forename: Nancy B
authors.initials: NB
authors.lastname: Rawlings
authors.forename: Ray
authors.initials: R
authors.lastname: Norbury
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Cowen
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Harmer
mesh_terms: D000293:Adolescent; D058669:Adrenergic alpha-2 Receptor Antagonists / Q000008:administration & dosage*; D000328:Adult; D000339:Affect / Q000187:drug effects; D000704:Analysis of Variance; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage*; D001931:Brain Mapping; D004311:Double-Blind Method; D004739:England; D019260:Expressed Emotion; D005149:Facial Expression; D005239:Fear; D005260:Female; D006240:Happiness; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000078785:Mirtazapine; D009434:Neural Pathways / Q000187:drug effects* / Q000502:physiology; D015990:Placebo Effect; D012702:Serotonin Antagonists / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D058669:Adrenergic alpha-2 Receptor Antagonists; D000929:Antidepressive Agents, Tricyclic; D012702:Serotonin Antagonists; D008803:Mianserin; D000078785:Mirtazapine
references.citation: Arch Gen Psychiatry. 1961 Jun;4:561-71
references.pmid: 13688369
references.citation: Clin Pharmacokinet. 2000 Jun;38(6):461-74
references.pmid: 10885584
references.citation: Magn Reson Med. 2003 Jan;49(1):193-7
references.pmid: 12509838
references.citation: J Affect Disord. 2009 Nov;118(1-3):87-93
references.pmid: 19250683
references.citation: Neuroimage. 2001 Dec;14(6):1370-86
references.pmid: 11707093
references.citation: Psychopharmacology (Berl). 1998 Oct;139(4):402-6
references.pmid: 9809861
references.citation: Hum Brain Mapp. 1994;1(3):210-20
references.pmid: 24578041
references.citation: Nature. 1996 Oct 31;383(6603):812-5
references.pmid: 8893004
references.citation: Psychopharmacology (Berl). 2009 Oct;206(2):197-204
references.pmid: 19585106
references.citation: Lancet. 2009 Feb 28;373(9665):746-58
references.pmid: 19185342
references.citation: Br J Psychiatry. 2007 Jun;190:531-2
references.pmid: 17541115
references.citation: Neuroimage. 2001 Nov;14(5):1070-9
references.pmid: 11697938
references.citation: Am J Psychiatry. 2003 Jan;160(1):64-75
references.pmid: 12505803
references.citation: Neuropsychopharmacology. 2003 Jan;28(1):148-52
references.pmid: 12496951
references.citation: Biol Psychiatry. 2001 Nov 1;50(9):651-8
references.pmid: 11704071
references.citation: Neuropsychopharmacology. 2008 Dec;33(13):3221-5
references.pmid: 18463627
references.citation: Biol Psychiatry. 2007 Jan 15;61(2):198-209
references.pmid: 17027931
references.citation: Am J Psychiatry. 2009 Oct;166(10):1178-84
references.pmid: 19755572
references.citation: J Clin Psychiatry. 2008 Sep;69(9):1404-15
references.pmid: 19193341
references.citation: IEEE Trans Med Imaging. 2004 Feb;23(2):137-52
references.pmid: 14964560
references.citation: CNS Drugs. 1996 May;5(5):389-402
references.pmid: 26071050
references.citation: Hum Brain Mapp. 2002 Nov;17(3):143-55
references.pmid: 12391568
references.citation: Psychopharmacology (Berl). 2008 Sep;199(4):495-502
references.pmid: 18575851
references.citation: Neuroimage. 2004 Apr;21(4):1732-47
references.pmid: 15050594
references.citation: Eur Neuropsychopharmacol. 2000 Mar;10(2):77-95
references.pmid: 10706989
references.citation: Psychol Med. 2010 Mar;40(3):425-32
references.pmid: 19627640
references.citation: Med Image Anal. 2001 Jun;5(2):143-56
references.pmid: 11516708
references.citation: Arch Gen Psychiatry. 2004 Sep;61(9):877-89
references.pmid: 15351766
references.citation: Biol Psychiatry. 2003 Sep 1;54(5):515-28
references.pmid: 12946880
references.citation: Neuropsychopharmacology. 2005 Sep;30(9):1724-34
references.pmid: 15827569
references.citation: Biol Psychiatry. 2008 Sep 15;64(6):505-12
references.pmid: 18550030
references.citation: Magn Reson Med. 2004 Sep;52(3):471-7
references.pmid: 15334564
references.citation: Biol Psychiatry. 2006 May 1;59(9):816-20
references.pmid: 16460693
references.citation: Trends Cogn Sci. 2005 Dec;9(12):585-94
references.pmid: 16289871
references.citation: J Pharmacol Exp Ther. 2003 Sep;306(3):954-64
references.pmid: 12750432
references.citation: Biol Psychiatry. 2003 Sep 1;54(5):504-14
references.pmid: 12946879
references.citation: Am J Psychiatry. 2003 May;160(5):990-2
references.pmid: 12727705
references.citation: Neuroimage. 2004;23 Suppl 1:S208-19
references.pmid: 15501092
references.citation: Br J Psychiatry. 2009 Jun;194(6):535-40
references.pmid: 19478294
references.citation: Psychopharmacology (Berl). 2009 May;203(4):685-91
references.pmid: 19031070
references.citation: Neuroimage. 2002 Oct;17(2):825-41
references.pmid: 12377157
references.citation: J Psychopharmacol. 2003 Jun;17(2):189-95
references.pmid: 12870566
references.citation: Am J Psychiatry. 2004 Jul;161(7):1256-63
references.pmid: 15229059
references.citation: Neuroimage. 2003 Aug;19(4):1317-28
references.pmid: 12948690
references.citation: Biol Psychiatry. 1998 Nov 1;44(9):812-24
references.pmid: 9807637